ANI Pharmaceuticals, Inc. says the re-filing of a supplemental new drug application for its lead product, Cortrophin (corticotropin) gel, with the US Food and Drug Administration in the second quarter of 2021 is on track. Calling it a “transformational opportunity” for the company, president and CEO Nikhil Lalwani said the launch had the potential to dramatically changing the size and scale of ANI. He pointed out that Cortrophin’s only competitor in the same class achieved $770m in revenues in 2020.
“We are eager to bring this much-needed product to patients in need,” said Lalwani. “Our dedicated Cortrophin technical team is...



